Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.41 |
| ▸ | MTOR | P42345 | 6/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10298533 | 0.86 | KDM4E (0.32) | PIK3CAPIK3R1KDM4EALDH1A1MAPT | |
| SCHEMBL627366 | 0.79 | PIK3CA (0.40) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL10288559 | 0.78 | KDM4E (0.39) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL10308589 | 0.77 | PIK3CA (0.49) | PIK3CAPIK3R1NPC1RAB9ARXFP1 | |
| SCHEMBL10288609 | 0.76 | PIK3CA (0.50) | PIK3CAPIK3R1NPC1RAB9ARXFP1 | |
| SCHEMBL6749633 | 0.72 | PIK3CA (0.44) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL1552162 | 0.70 | PIK3CA (0.74) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL10288142 | 0.69 | PDE10A (0.36) | PIK3CAPIK3CDPIK3CBPIK3CGRXFP1 | |
| SCHEMBL6752269 | 0.69 | PIK3CA (0.61) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL10298513 | 0.67 | PDE10A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-8796271-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796268-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120178723-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172345-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2012021696-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172345-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | PIK3CA 5/4885PIK3R1 1/4885MTOR 86/4885 |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | PIK3CA 5/4885PIK3R1 1/4885MTOR 86/4885 |
| US-20120178723-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | PIK3CA 5/4885PIK3R1 1/4885MTOR 82/4885 |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | PIK3CA 5/4885PIK3R1 1/4885MTOR 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.